ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

Key Inclusion Criteria: 1. AIH diagnosed per International Autoimmune Hepatitis Group 2. Liver biopsy with Ishak modified HAI indicating active AIH 3. Incomplete response to OR intolerance of standard therapy (per AASLD) Key Exclusion Criteria 1. Prior use of any B-cell depleting therapy (e.g., rituximab or other anti-CD20 mAb, anti-CD22 mAb or anti-CD52 mAb) within 1 year prior to Screening or as long as B-cell count \<50 cells/µL 2. Required regular use of medications with known hepatotoxicity 3. Decompensated cirrhosis 4. Diagnosis of overlap syndrome with AIH (e.g., AIH+PBC, AIH+PSC). 5. Drug related AIH at screening or a history of drug related AIH. 6. History of drug abuse or unhealthy alcohol use 7. History of malignancy of any organ system 8. Pregnant or nursing (lactating) women